Comparison

Pramlintid vs. Semaglutid

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Pramlintid	Semaglutid
Switzerland	—	Prescription
Germany	Unapproved	Prescription
United States	Prescription	Prescription

Full entries

Frequently asked questions

What is the difference between Pramlintid and Semaglutid?: Pramlintid is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pramlintid or Semaglutid?: The highest available evidence level is "Human RCT" for Pramlintid and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pramlintid and Semaglutid in Germany and the United States?: Germany: Pramlintid — Unapproved, Semaglutid — Prescription. United States: Pramlintid — Prescription, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Pramlintid

Semaglutid

Switzerland

—

Prescription

Germany

Unapproved

Prescription

United States

Prescription

Frequently asked questions

What is the difference between Pramlintid and Semaglutid?

Pramlintid is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pramlintid or Semaglutid?

The highest available evidence level is "Human RCT" for Pramlintid and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pramlintid and Semaglutid in Germany and the United States?

Germany: Pramlintid — Unapproved, Semaglutid — Prescription. United States: Pramlintid — Prescription, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.